Advanced search
Publication Cover
Journal of Medical Economics Volume 18, 2015 - Issue 11
Submit an article Journal homepage
983
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies

Jing DengDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
,
Shuyan GuCenter for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China
,
Hui ShaoDepartment of Global Health Systems and Development, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA
,
Hengjin DongCenter for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China
,
Dajin ZouDepartment of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, PR China
&
Lizheng ShiDepartment of Global Health Systems and Development, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USACorrespondence[email protected]
Pages 974-989 | Accepted 26 Jun 2015, Published online: 20 Aug 2015

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Hui Shao, Suodi Zhai, Dajin Zou, Mohammed Umer Mir, Nadine K. Zawadzki, Qian Shi, Shuqian Liu & Lizheng Shi. (2017) Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current Medical Research and Opinion 33:2, pages 359-369.
Read now

Articles from other publishers (11)

Zixuan He, Xianqin Huang, Dingyi Chen, Guoan Wang, Yuezhen Zhu, Huangqianyu Li, Sheng Han, Luwen Shi & Xiaodong Guan. (2023) Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review. BMJ Global Health 8:11, pages e012780.
Crossref
Lei Liu, Zhen Ruan, Carolina Oi Lam Ung, Yawen Zhang, Yang Shen, Sheng Han, Ruxu Jia, Jingtao Qiao, Hao Hu & Lixin Guo. (2022) Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China. Diabetes Therapy 14:1, pages 93-107.
Crossref
Zhen Ruan, Carolina Oi Lam Ung, Yang Shen, Yawen Zhang, Weihao Wang, Jingyi Luo, Huimin Zou, Yan Xue, Yao Wang, Hao Hu & Lixin Guo. (2022) Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China. Diabetes Therapy 13:10, pages 1737-1753.
Crossref
Jiehua Cheng, Yu Zhang, Ailin Zhong, Miao Tian, Guanyang Zou, Xiaping Chen, Hongxing Yu, Fujian Song & Shangcheng Zhou. (2021) Quality of Health Economic Evaluations in Mainland China: A Comparison of Peer-Reviewed Articles in Chinese and in English. Applied Health Economics and Health Policy 20:1, pages 35-54.
Crossref
Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou & Shihchen Kuo. (2021) Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovascular Diabetology 20:1.
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nathorn Chaiyakunapruk, Mark McEvoy, John Attia & Ammarin Thakkinstian. (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Research & Care 8:1, pages e001020.
Crossref
Hui Shao, Ji Lin, Xiaohui Zhuo, Deborah B. Rolka, Edward W. Gregg & Ping Zhang. (2019) Influence of Diabetes Complications on HbA 1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis . Diabetes Care 42:11, pages 2136-2142.
Crossref
Volker Foos, Ke Wang, Phil McEwan, Yanlei Zhang, Ping Xin, Xiaohua Jiang, Shuli Qu, Tengbin Xiong, Raf De Moor, Mafalda Ramos, Mark Lamotte & Linong Ji. (2019) Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. Value in Health Regional Issues 18, pages 36-46.
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang & Hengjin Dong. (2017) Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. Diabetes, Obesity and Metabolism 19:12, pages 1688-1697.
Crossref
Yunyu Huang, Pepijn Vemer, Jingjing Zhu, Maarten J. Postma & Wen Chen. (2016) Economic Burden in Chinese Patients with Diabetes Mellitus Using Electronic Insurance Claims Data. PLOS ONE 11:8, pages e0159297.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.